Minapharm Pharmaceuticals results, Q4 2023
Net profit, assets, equity and cash flow for Q4 2023, against the same period a year earlier, from the published financial statements.
Net profit-175 millionEGP · −206.9% vs the same period a year earlier
Total assets8.7 billionEGP · +27.9% vs the same period a year earlier
Shareholders' equity3.52 billionEGP · +15.7% vs the same period a year earlier
Operating cash flow84.46 millionEGP · −56.8% vs the same period a year earlier
In short
- Minapharm Pharmaceuticals's net profit for Q4 2023 was about -175 million EGP, down −206.9% from 164 million EGP in Q4 2022.
- Total assets at the end of Q4 2023 were about 8.7 billion EGP, and shareholders' equity about 3.52 billion EGP.
- Operating cash flow for Q4 2023 was positive at 84.46 million EGP.
Key lines against the same period a year earlier
This periodQ4 2022Change
Net profit-175 million164 million−206.9%
Gross profit207 million487 million−57.4%
Total assets8.7 billion6.81 billion+27.9%
Total liabilities5.19 billion3.77 billion+37.7%
Shareholders' equity3.52 billion3.04 billion+15.7%
Total liabilities and equity8.7 billion6.81 billion+27.9%
Operating cash flow84.46 million195 million−56.8%
Investing cash flow-267 million-450 million+40.8%
Financing cash flow559 million434 million+28.9%
Net change in cash377 million179 million+110.5%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Minapharm Pharmaceuticals's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy